Binds Cancer Cell Or Component Or Product Thereof (e.g., Cell-surface Antigen, Etc.) Patents (Class 530/388.8)
-
Patent number: 11702480Abstract: The present disclosure relates to an engineered antibody that co-engages a cell type-selective (or specific) antigen (guide) and a signaling receptor (effector) on a target cell. In some instances, the engineered antibody is capable of modulating a signaling pathway on a target cell. In other embodiments, an engineered antibody of the present disclosure is administered to a subject for the treatment of a disease or condition.Type: GrantFiled: November 17, 2017Date of Patent: July 18, 2023Assignee: The Regents of the University of CaliforniaInventors: Bin Liu, Namkyung Lee, Yang Su, Scott Bidlingmaier
-
Patent number: 11634502Abstract: Provided herein are heterodimeric bispecific antibodies that can mediate cytolysis of a target cell by an immune effector cell, nucleic acids encoding such antibodies, methods of making such antibodies, and methods of using such antibodies. These antibodies comprise two different polypeptide chains, each comprising two immunoglobulin variable regions and, optionally, a half life-extending moiety.Type: GrantFiled: March 13, 2014Date of Patent: April 25, 2023Assignee: AMGEN INC.Inventors: Wei Yan, Martin J. Pentony, Luis G. Borges, Mark L. Michaels
-
Patent number: 11572415Abstract: The application pertains to a trispecific antibody molecule which may comprise a diabody-unit integrated into a polypeptide chain having at least six variable domains linked one after another. In certain instances two single-chain Fv (scFv) fragments are distally connected to the diabody-unit providing two further antigen binding sites (FIGS. 1 and 2).Type: GrantFiled: April 11, 2018Date of Patent: February 7, 2023Assignee: AFFIMED GMBHInventors: Kristina Ellwanger, Ivica Fucek, Thorsten Ross, Thomas Mueller, Erich Rajkovic, Uwe Reusch, Martin Treder, Michael Weichel
-
Patent number: 11530264Abstract: A multifunctional polypeptide chain or a protein. A polypeptide chain X, comprising an antigen 1 binding domain R1, an auxiliary peptide chain linking domain R2 and an antigen 2 binding domain R3. The auxiliary peptide chain linking domain R2 is a cytokine or a cytokine binding domain in a cytokine receptor. A protein, which is a heterodimer composed of the polypeptide chain X as a main peptide chain and an auxiliary peptide chain Y. The auxiliary peptide chain Y comprises an antigen 3 binding domain R4 and a main peptide chain X linking domain R5, or the auxiliary peptide chain Y is the main peptide chain linking domain R5. The multifunctional protein mediates specific cell killing by binding to different tumor antigens with the two antigen binding domains of tumor-associated antigens therein. The multifunctional protein can function as a cytokine by introducing a cytokine or a cytokine receptor complex.Type: GrantFiled: December 27, 2017Date of Patent: December 20, 2022Assignee: SHENZHEN BEIKE BIOTECHNOLOGY CO., LTDInventors: Fengyu Zhang, Bin Gao, Lei Wang, Yasong Wu, Qing Wei
-
Patent number: 11505616Abstract: The present invention relates to a bispecific molecule comprising at least one anti-CD38 domain and at leak one anti-PD-L1 domain, which are capable of simultaneous binding to CD38 and PD-L1 antigens, respectively.Type: GrantFiled: March 27, 2017Date of Patent: November 22, 2022Assignee: BIOMUNEX PHARMACEUTICALSInventors: Eugene Zhukovsky, Olivier Leger, Richard J. Morse
-
Patent number: 11091554Abstract: The present invention relates to antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.Type: GrantFiled: June 29, 2018Date of Patent: August 17, 2021Assignee: Medlmmune, LLCInventors: Partha S. Chowdhury, David Tice, Zhan Xiao, Philipp Steiner, Krista Kinneer, Marlon Rebelatto
-
Patent number: 10927185Abstract: [Problem] Provided is a bispecific antibody with a novel format that retains high binding affinity to both antigens, and can be efficiently produced in a commercial production process.Type: GrantFiled: November 20, 2015Date of Patent: February 23, 2021Assignee: Astellas Pharma Inc.Inventors: Yasuhiro Ito, Atsuo Yonezawa
-
Patent number: 10519251Abstract: The present invention provides multivalent and multispecific binding proteins that are capable of binding two or more antigens, or two or more epitopes. The present invention also provides methods of making and using such multivalent and multispecific binding proteins, including methods of using such binding proteins for prevention or treatment of various diseases, or for detecting specific antigens in vitro or in vivo.Type: GrantFiled: December 24, 2014Date of Patent: December 31, 2019Assignee: EpimAb Biotherapeutics, Inc.Inventor: Chengbin Wu
-
Patent number: 10385137Abstract: The invention concerns antibody formats comprising VH sequence of Camelidae, such as llamas; antibodies of various formats have anti-CEA or anti-CD16 VH sequences thereof; vectors expressing the antibody formats, and methods for producing the same.Type: GrantFiled: September 16, 2015Date of Patent: August 20, 2019Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Centre National de la Recherche Scientifique (CNRS), Universite d'Aix Marseille, Universite de Montpellier, Institut Regional du Cancer de Montpellier-Val D'Aurelle, Institut Paoli CalmettesInventors: Daniel Baty, Ghislaine Behar, Martine Mansais, Andre Pelegrin, Jean-luc Teillaud, Isabelle Teulon
-
Patent number: 9598501Abstract: The present invention provides an antibody-immobilized carrier that can be used in antibody screening, a method of producing the antibody-immobilized carrier, and use of the antibody-immobilized carrier. Efficient antibody screening can be carried out particularly by an antibody-immobilized carrier including two or more antibody immobilized regions onto each of which a heavy-chain low-molecular-weight antibody and a light-chain low-molecular-weight antibody are separately immobilized, the two or more antibody immobilized regions each being included in an independent manner, the heavy-chain low-molecular-weight antibody including a heavy-chain variable region, the light-chain low-molecular-weight antibody including a light-chain variable region, the heavy-chain low-molecular-weight antibody and the light-chain low-molecular-weight antibody each being derived from an antibody recognizing a different antigen.Type: GrantFiled: September 30, 2014Date of Patent: March 21, 2017Assignees: NATIONAL UNIVERSITY CORPORATION KYOTO INSTITUTE OF TECHNOLOGY, DENKA SEIKEN CO., LTDInventors: Yoichi Kumada, Michimasa Kishimoto, Kyoko Hamasaki, Aya Nakagawa
-
Patent number: 9320812Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of such modulators to treat hyperproliferative disorders are provided.Type: GrantFiled: December 7, 2011Date of Patent: April 26, 2016Assignee: Stemcentrx, Inc.Inventors: Johannes Hampl, Scott J. Dylla, Orit Foord, Robert A. Stull
-
Patent number: 9259440Abstract: The present invention relates to products and methods for preventing, ameliorating and/or treating infections and other diseases. In one aspect, the products of the present invention relates to compositions comprising germ free colostrum. In another aspect, the products of the present invention relates to compositions comprising synthetically multimerized immunoglobulins. In a third aspect, the products of the present invention relates to compositions comprising germ free colostrum enriched with synthetically multimerized immunoglobulins. The invention also relates to use of said compostions as a pharmaceutical e.g. for prophylactic or ameliorating treatment of infections and other diseases. In addition the invention comprises methods for production of said compositions.Type: GrantFiled: June 28, 2013Date of Patent: February 16, 2016Assignee: MULTIMERICS ApSInventor: Kirsten Bisgaard-Frantzen
-
Patent number: 9261507Abstract: A method for diagnosing a cancer characterized by over expression of CEACAM1 using an anti-CEACAM1 antibody or antibody fragment that recognizes CEACAM1 and comprises the same CDR sequences in the same orientation as the CDRs of the antibody produced from a hybridoma cell which has been deposited under ATCC Accession Number PTA-9974.Type: GrantFiled: October 23, 2013Date of Patent: February 16, 2016Assignees: Tel Hashomer Medical Research Infrastructure and Services LTD., RAMOT AT TEL AVIV UNIVERSITY LTD.Inventors: Gal Markel, Rona Ortenberg, Jacob Schachter
-
Patent number: 9217033Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Glypican-3 with high affinity. Nucleic acid molecules encoding Glypican-3 antibodies, expression vectors, host cells and methods for expressing the Glypican-3 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the Glypican-3 antibodies are also provided. Methods for detecting Glypican-3, as well as methods for treating various Glypican-3-related conditions, including hepatocellular cancer, are disclosed.Type: GrantFiled: February 10, 2014Date of Patent: December 22, 2015Assignee: E. R. SQUIBB & SONS, L.L.C.Inventors: Jonathan Alexander Terrett, Li-Sheng Lu, Haichun Huang, Dapeng Yao, Chin Pan, Heidi N. LeBlanc, Tim W. Sproul, Mark Yamanaka
-
Patent number: 9206260Abstract: The present invention provides antigen binding molecules (ABMs) which bind membrane-bound CEA, including ABMs with improved therapeutic properties, and methods of using the same.Type: GrantFiled: December 20, 2013Date of Patent: December 8, 2015Assignee: Roche Glycart AGInventors: Thomas U. Hofer, Ralf Hosse, Ekkehard Moessner, Pablo Umana
-
Patent number: 9062109Abstract: The present invention relates to a novel antibody against ephrin B2 and its use to detect the protein and as a medicament for inhibiting angiogenesis and lymphangiogenesis in the treatment of diseases in which these processes are implicated, for example, cancer.Type: GrantFiled: September 20, 2011Date of Patent: June 23, 2015Assignee: Fundacion Centro Nacional De Investigaciones Oncologicas (CNIO)Inventors: Jorge Luis Martinez Torrecuadrada, Maria Angeles Abengozar Infantes
-
Patent number: 9045546Abstract: The present invention provides molecules that bind to TMEM16A (“TMEM16A binding molecules”), particularly human or humanized antibodies and antibody drug conjugates that bind to human TMEM16A and modulate its functions. Epitopes of TMEM16A and molecules that bind these epitopes are also provided herein.Type: GrantFiled: November 30, 2012Date of Patent: June 2, 2015Assignee: NOVARTIS AGInventors: Larry Alexander Gaither, Christopher John Rothwell
-
Patent number: 9040671Abstract: The present disclosure relates to a Co-029 inhibitor for inhibiting the migration of cancer cells which express Co-029. The disclosure relates to a Co-029 inhibitor for the treatment of cancer and/or the prevention of cancer metastasis and pharmaceutical compositions comprising said inhibitor and provides Co-029 antibodies. The disclosure provides a method for predicting the response of a patient afflicted with or susceptible to be afflicted with cancer to a medical treatment with a Co-029 inhibitor, a method for diagnosing a cancer in a patient and a method for predicting the survival in a cancer patient.Type: GrantFiled: July 22, 2011Date of Patent: May 26, 2015Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Paris X1 Paris SudInventors: Eric Rubinstein, Céline Greco, François Le Naour, Claude Boucheix
-
Patent number: 9034328Abstract: The present invention relates to an antibody or an antibody fragment thereof which recognizes an extracellular domain of erbB3 and inhibit EGF-like ligand-dependent phosphorylation of erbB3, a DNA encoding the antibody or the antibody fragment thereof, a method of producing the antibody or the antibody fragment thereof, a therapeutic drug including the antibody or the antibody fragment thereof, and therapeutic application using the antibody or the antibody fragment thereof.Type: GrantFiled: June 20, 2012Date of Patent: May 19, 2015Assignee: KYOWA HAKKO KIRIN CO., LTDInventor: Nobuaki Takahashi
-
Patent number: 9029513Abstract: A cell growth inhibitor that includes, as an antibody component, an artificially produced anti-EGFR antibody having specific binding capacity to EGFR which is characterized in that an epitope therefor is in a cysteine-rich subdomain 2 (C2 domain) and/or in a ligand-binding domain 1 (L1 domain) among four subdomains contained in the extracellular domain of EGFR.Type: GrantFiled: June 3, 2011Date of Patent: May 12, 2015Assignees: Toagosei Co. Ltd., Keio UniversityInventors: Nobuyoshi Shimizu, Atsushi Takayanagi, Tetsuhiko Yoshida
-
Patent number: 9023999Abstract: The present invention provides a monoclonal antibody which specifically recognizes CD27 containing an O-linked sugar chain to which galactose is not bound and binds to its extracellular region, or a method for using the same. The present invention can provide a monoclonal antibody or an antibody fragment thereof, which specifically recognizes a polypeptide encoded by CD27 gene containing an O-linked sugar chain to which galactose is not bound, and binds to its extracellular region; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which comprises the DNA; a transformant obtainable by transforming the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a diagnostic agent or a therapeutic agent comprising the antibody or the antibody fragment thereof as an active ingredient.Type: GrantFiled: June 30, 2009Date of Patent: May 5, 2015Assignee: Kyowa Hakko Kirin Co., LtdInventors: Katsuhiro Mori, Naoko Hiura, Tsuguo Kubota, Akiko Furuya, Yutaka Kanda, Mitsuo Satoh
-
Patent number: 9017677Abstract: A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising an interleukin-6 (IL-6) antagonist, for example an antibody directed against IL-6 receptor, an antibody directed against IL-6, an antibody directed against gp130, and the like.Type: GrantFiled: January 25, 2006Date of Patent: April 28, 2015Assignee: Chugai Seiyaku Kabushiki KaishaInventor: Masahiko Mihara
-
Patent number: 9017957Abstract: An object of the present invention is to provide an antibody that can be stably supplied and can react with prostasin under non-denaturation and denaturation conditions, and an antigen peptide for preparation of the antibody. The present invention relates to a peptide consisting of the amino acid sequence shown in SEQ ID NO: 1 or a peptide consisting of an amino acid sequence that has a deletion, a substitution, or an addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1 and having antigenicity of prostasin. Furthermore, the present invention relates to an antibody prepared using the peptide as an antigen.Type: GrantFiled: May 1, 2007Date of Patent: April 28, 2015Assignees: Hitachi Chemical Company, Ltd., Kimio Tomita, Kenichiro KitamuraInventors: Hiromi Iijima, Noriya Ohta, Kimio Tomita, Kenichiro Kitamura
-
Patent number: 8987423Abstract: Antigen binding proteins, such as antibodies, which bind to human MAGE-A3, polynucleotides encoding such antigen binding proteins, and uses and manufacture thereof.Type: GrantFiled: July 20, 2011Date of Patent: March 24, 2015Assignee: GlaxoSmithKline Biologicals, S.A.Inventors: Alain Bergeron, Normand Blais, Remi M. Palmantier, Anthony Pilorget, Yves Fradet
-
Patent number: 8975382Abstract: The present invention relates to amino acid sequences and Nanobodies that are directed against Epidermal Growth Factor Receptor 2 (HER2), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.Type: GrantFiled: November 27, 2008Date of Patent: March 10, 2015Assignee: Ablynx N.V.Inventors: Hilde Adi Pierrette Revets, Carlo Boutton, Hendricus Renerus Jacobus Mattheus Hoogenboom
-
Patent number: 8962806Abstract: The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor CCR4. This antibody is derived from Mab 1567 and recognizes the same epitope. Binding of the invented antibody to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.Type: GrantFiled: December 29, 2008Date of Patent: February 24, 2015Assignees: Dana-Farber Cancer Institute, Inc., The Bingham and Women's HospitalInventors: Wayne Marasco, Jianhua Sui, Quan Zhu, Thomas Kupper
-
Patent number: 8961980Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, and hepatocellular cancer.Type: GrantFiled: December 11, 2012Date of Patent: February 24, 2015Assignees: Ganymed Pharmaceuticals AG, Johannes Gutenberg-Universitat MainzInventors: Ugar Sahin, Michael Koslowski, Ozlem Tureci
-
Patent number: 8951972Abstract: Methods of treating cancer comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are provided. Dosage packs comprising an FGFR1 ECD and/or an FGFR1 ECD fusion molecule and/or at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are also provided. In some embodiments, a dosage pack comprises instructions for administering FGFR1 ECD and/or FGFR1 ECD fusion molecule with at least one additional therapeutic agent.Type: GrantFiled: November 14, 2011Date of Patent: February 10, 2015Assignee: Five Prime Therapeutics, Inc.Inventors: Li Long, Thomas Brennan
-
Patent number: 8945570Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.Type: GrantFiled: October 26, 2012Date of Patent: February 3, 2015Assignee: Agensys, Inc.Inventors: Aya Jakobovits, Robert Kendall Morrison, Arthur B. Raitano, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen Jane Meyrick Morrison, Mary Faris, Wangmao Ge, Jean Gudas, Steven B. Kanner
-
Patent number: 8945566Abstract: The invention provides a method for increasing the bioactivity (e.g. the biosafety and efficacy) of a therapeutic IgE antibody of the invention in the treatment of a patient. Methods of the invention include: i) administering to the patient a therapeutic IgE antibody in combination with at least one bioactivity-enhancing agent, ii) strategic treatment regimens and protocols for the dosing and administration of a therapeutic IgE antibody of the invention, and iii) the use of a therapeutic IgE antibody having a variable region comprising at least one antigen binding region specific for binding an epitope of an antigen wherein the epitope is not highly repetitive or is non-repetitive.Type: GrantFiled: April 26, 2012Date of Patent: February 3, 2015Assignee: Quest PharmaTech, Inc.Inventors: Birgit C. Schultes, Christopher F. Nicodemus
-
Patent number: 8945569Abstract: Antibodies that specifically bind to an extracellular domain of human Jagged 1 or human Jagged2 and modulate Jagged activity, and methods of using said antibodies to inhibit tumor growth are disclosed. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an anti-Jagged antibody to a patient having a tumor or cancer.Type: GrantFiled: November 19, 2010Date of Patent: February 3, 2015Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Timothy Charles Hoey, Aaron Ken Sato, Alexandra Lazetic, Zhimin Ji
-
Patent number: 8940298Abstract: The present invention provides novel high affinity antibodies and fragments thereof that bind to the cancer antigen PSCA. The antibodies of the present invention may be used for cancer diagnosis, prognosis, treatment, visualization, and the like. The present invention also provides methods for the detection, visualization, and treatment of various cancers expressing PSCA.Type: GrantFiled: September 4, 2008Date of Patent: January 27, 2015Assignee: The Regents of the University of CaliforniaInventors: Anna M. Wu, Robert E. Reiter, Eric J. Lepin, James D. Marks, Yu Zhou
-
Patent number: 8940871Abstract: The invention provides novel humanized antibody fragments that specifically bind prostate cell-surface antigen (PSCA), a protein which is overexpressed in variety of cancers, including prostate, bladder, and pancreatic cancer. Methods are provided for the use of the compositions of the invention for the treatment of cancer, diagnosis of cancer, to provide a prognosis of cancer progression, and for cancer imaging.Type: GrantFiled: March 20, 2007Date of Patent: January 27, 2015Assignee: The Regents of the University of CaliforniaInventors: Anna M. Wu, Robert E. Reiter
-
Patent number: 8920803Abstract: A method for the treatment of a condition which is characterized by CD 123-expressing cells in a patient comprises administering to the patient (i) an antibody or antibody fragment which binds selectively to IL-3R?(CD 123), and (ii) an immunostimulating complex which comprises saponin, a sterol and a phospholipid.Type: GrantFiled: June 15, 2011Date of Patent: December 30, 2014Assignee: CSL LimitedInventors: Debra Pauline Drane, Eugene Maraskovsky, Jefferey Stephen Boyle
-
Patent number: 8921525Abstract: [Problem] Disclosed is an antibody that exhibits excellent cytotoxicity and cell growth inhibition and that is based on an anti-human epithelial cell growth factor receptor (1) (Her1) antibody (528). Further disclosed is a method for producing same, and the like. [Solution] The mutant of an H chain humanized variable region (5H) or an L chain humanized variable region (5L) of the anti-human epithelial cell growth factor receptor (1) (Her1) antibody (528) is the aforementioned antibody characterized by having one to a plurality (for example: 1 to 5, or 1 to 3) of amino acid mutations within CDR2. Further disclosed are antibody molecules containing said region, a nucleic acid molecule coding for these polypeptides, a method for producing said antibody molecules, and the like.Type: GrantFiled: November 11, 2010Date of Patent: December 30, 2014Assignee: Tohoku UniversityInventors: Izumi Kumagai, Takeshi Nakanishi, Ryutaro Asano, Mitsuo Umetsu
-
Publication number: 20140363873Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.Type: ApplicationFiled: May 8, 2014Publication date: December 11, 2014Applicant: Genentech, Inc.Inventors: Mark Dennis, Bonnee Rubinfeld, Paul Polakis
-
Patent number: 8901278Abstract: The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising an IgG1 antibody specifically binding to human CEA, wherein the variable region of said IgG1 antibody comprises at least (i) a CDR-H1 having the amino acid sequence “SYWMH” (SEQ ID NO: 29) and a CDR-H2 having the amino acid sequence “FIRNKANGGTTEYAASVKG” (SEQ ID NO: 28) and a CDR-H3 having the amino acid sequence “DRGLRFYFDY” (SEQ ID NO: 27) or (ii) a CDR-H1 having the amino acid sequence “TYAMH” (SEQ ID NO: 31) and a CDR-H2 having the amino acid sequence “LISNDGSNKYYADSVKG” (SEQ ID NO: 30) and a CDR-H3 having the amino acid sequence “DRGLRFYFDY” (SEQ ID NO: 27). Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the IgG1 antibody molecules bearing specificities for the human CEA antigen are disclosed.Type: GrantFiled: December 13, 2011Date of Patent: December 2, 2014Assignee: Amgen Research (Munich) GmbHInventors: Doris Rau, Susanne Mangold, Peter Kufer, Tobias Raum
-
Patent number: 8895703Abstract: The CA125 gene has been cloned and multiple repeat sequences as well as the carboxy terminus have been identified. The CA125 molecule comprises three major domains: an extracellular amino terminal domain (Domain 1); a large multiple repeat domain (Domain 2); and a carboxy terminal domain (Domain 3) which includes a transmembrane anchor with a short cytoplasmic domain. An amino terminal extension is present. The molecular structure is dominated by a repeat domain comprising 156 amino acid repeat units. More than 60 repeat units have been identified, sequenced, and contiguously placed in the CA125 domain structure. The repeat units encompass an interactive disulfide bridged C-enclosure and the site of OC125 and M11 binding. The repeat sequences demonstrated 70-85% homology to each other. Expression of the repeats was demonstrated in E. coli. The CA125 molecule is anchored at its carboxy terminal through a transmembrane domain and a short cytoplasmic tail.Type: GrantFiled: October 19, 2007Date of Patent: November 25, 2014Assignee: The Board of Trustees for the University of ArkansasInventors: Timothy O'Brien, John Beard, Lowell Underwood
-
Patent number: 8883980Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.Type: GrantFiled: August 17, 2007Date of Patent: November 11, 2014Assignee: Roche Glycart AGInventors: Pablo Umaña, Peter Brünker, Claudia Ferrera Koller, Tobias Suter, Ursula Püntener, Ekkehard Mössner
-
Patent number: 8877199Abstract: The invention relates to antibodies that are reactive to the cell surface of CD19+ B cells, including B-cell chronic lymphocytic leukemia (B-CLL) cells, and compositions and methods for using such antibodies, including in the diagnosis and treatment of disorders associated with CD19+ B cells, such as B-CLL.Type: GrantFiled: May 12, 2010Date of Patent: November 4, 2014Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human ServicesInventors: Christoph Rader, Sivasubramanian Baskar, Michael R. Bishop, Ivan Samija, Jessica M. Suschak
-
Patent number: 8871908Abstract: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.Type: GrantFiled: November 7, 2012Date of Patent: October 28, 2014Assignee: Rinat Neuroscience Corp.Inventors: Shu-Hui Liu, Wei-Hsien Ho, Pavel Strop, Magdalena Grazyna Dorywalska, Arvind Rajpal, David Louis Shelton, Thomas-Toan Tran
-
Patent number: 8871204Abstract: The present invention relates to modified Fc-containing molecules including modified antibodies characterized by increased resistance to host and pathogen-derived proteases, ability to interact with Fc?R receptors except with Fc?RI, and lack of induction of IL-10 secretion by macrophages, and methods of using and making them.Type: GrantFiled: July 23, 2012Date of Patent: October 28, 2014Assignee: Janssen Biotech, Inc.Inventors: Randall Brezski, Robert Jordan, William Strohl
-
Patent number: 8865873Abstract: This invention provides a method that allows selection of antibodies against cells (e.g., tumor cells) in situ using laser capture microdissection. By restricting antibody selection to binders of internalizing epitopes, a panel of phage antibodies was generated that targets clinically represented prostate cancer antigens.Type: GrantFiled: March 15, 2010Date of Patent: October 21, 2014Assignee: The Regents of the University of CaliforniaInventors: Bin Liu, James D. Marks
-
Patent number: 8858942Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to ErbB2, preferably human ErbB2. In another embodiment, the antibodies or antigen-binding portions thereof inhibit ErbB2. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins or portions thereof derived from human anti-ErbB2 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-ErbB2 antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.Type: GrantFiled: December 11, 2012Date of Patent: October 14, 2014Assignee: MedImmune LimitedInventors: Susan Ann Cartlidge, Jianying Dong, Mark Hickinson, Ian Foltz, Jaspal Singh Kang
-
Patent number: 8853364Abstract: PSCA and its encoded protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.Type: GrantFiled: September 17, 2009Date of Patent: October 7, 2014Assignee: Agensys, Inc.Inventors: Wangmao Ge, Pia M. Challita-Eid, Arthur B. Raitano, Aya Jakobovits
-
Patent number: 8846872Abstract: The disclosure relates to antibodies to the preferentially expressed antigen in melanoma (PRAME), and the synovial sarcoma X breakpoint 2 (SSX-2) antigens, methods of use, and diagnostic kits thereof. In exemplary embodiments, the disclosure relates to monoclonal antibodies to specific epitopes of the PRAME and SSX-2 antigens and methods of using such antibodies.Type: GrantFiled: November 18, 2010Date of Patent: September 30, 2014Assignee: MannKind CorporationInventors: Nathalie Kertesz, Sutao Zhu, Chih-Sheng Chiang
-
Patent number: 8841421Abstract: A method of identifying a compound for use in therapy which modulates the interaction of S1OO A9 with a ligand comprising:—determining whether a candidate compound is capable of modulating the interaction of S1OO A9 with RAGE or the interaction of S1OO A9 with a TLR (Toll like receptor), or—determining whether a candidate compound is capable of binding to S100A9 in a manner which disrupts binding of S1OO A9 with RAGE or the binding of S100A9 with a TLR, to thereby identify whether the compound may be used in therapy.Type: GrantFiled: April 24, 2008Date of Patent: September 23, 2014Assignee: Active Biotech, ABInventors: Per Bjork, Frederik Ivars, Tomas Leanderson
-
Patent number: 8828717Abstract: The present disclosure provides humanized COL-1 monoclonal antibodies that retain CEA binding affinity, compared to a parent antibody. Also disclosed herein are humanized COL-1 monoclonal antibodies that have reduced immunogenicity, compared to a parent antibody. The disclosed humanized COL-1 antibodies include substitution of framework residues with residues from the corresponding positions of a homologous human sequence. In several embodiments, methods are disclosed for the use of a humanized COL-1 antibody in the detection or treatment of a CEA-expressing tumor or cell in a subject. Also disclosed is a kit including the humanized COL-1 antibodies described herein.Type: GrantFiled: November 15, 2010Date of Patent: September 9, 2014Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Jeffrey Schlom, Eduardo A. Padlan, Rafia Mehdi Kashmiri
-
Patent number: 8822648Abstract: An anti-CEA scFv having an uncleaved Pel B leader sequence is surprisingly stable and is highly specific for CEA and CEACAM1.Type: GrantFiled: December 21, 2012Date of Patent: September 2, 2014Assignees: Instituto Superiore di Sanita, Diatheva s.r.l.Inventors: Maurizio Cianfriglia, Michela Flego, Alessandro Ascione, Valentina Fiori, Sabrina Domicini, Alessandra Mallano, Diego Moricoli, Silvia Zamboni
-
Publication number: 20140234327Abstract: The invention discloses a monoclonal antibody against human non-small cell lung carcinoma and a use of the monoclonal antibody. The monoclonal antibody is secreted by a hybridoma cell strain which is deposited as CCTCC Access Number No.: C201172. It has high yield and high titer, and has specific reactivity against lung adenocarcinoma and squamous carcinoma cell lines. Therefore, the monoclonal antibody may be applied in preparing drugs for treating human non-small cell lung carcinoma.Type: ApplicationFiled: January 12, 2012Publication date: August 21, 2014Inventors: Shiyan Pan, Peijun Huang, Fang Wang